Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance in PCNSL
NCT05260619Phase 2Recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in primary central nervous system lymphoma (PCNSL), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2022; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05260619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260619.